Isabl
Cancer tests based on whole genome and transcriptome data.
New York, United States · Founded 2020 · $2.0M raised
- Headquarters
- New York, New York
- Employees
- 1–10
- Founded
- 2020
- Website
- isabl.io
- Total Funding
- $2.0M
About
Isabl has developed software that can analyze the entire genome of cancer patients. Today, when people get cancer, they get a genetic test of their tumor that analyzes only a few possible mutations. With Isabl, you run the tumor through an Illumina sequencer and get the whole genome, then our software is able to analyze all the mutations. Our breakthrough technology provides unprecedented clarity into tumor biology to aid treatment planning. This opens up opportunities for precision diagnostics, disease surveillance and biomarker discovery.
Summary
Isabl is a Biotech company based in New York, United States, founded in 2020. It has raised $2.0M in total.
Tech & App Stack
3 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Funding History
No funding data available yet.
Know something? Help us improve our data.
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Specialty pharmaceutical company
Biopharmaceutical services company
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...